Loading...
•
Sep 30, 2020
Mersana Q3 2020 Earnings Report
Mersana reported financial results for Q3 2020 and provided a business update.
Key Takeaways
Mersana Therapeutics reported cash and cash equivalents of $270.9 million as of September 30, 2020. Net cash used in operating activities in the third quarter of 2020 was $20.2 million. The company expects that its cash and cash equivalents will enable it to fund its current operating plan commitments for more than two years.
Presented additional data from XMT-1536 Phase 1 study at ESMO demonstrating compelling and consistent activity and tolerability profile in ovarian cancer
Received FDA Fast Track Designation for XMT-1536 for patients with heavily-pretreated ovarian cancer
Ended Q3 2020 with $271 million in cash
XMT-1592, a Dolasynthen ADC targeting NaPi2b, is actively enrolling patients in a Phase 1 dose escalation study.
Mersana
Mersana
Forward Guidance
The Company expects that its cash and cash equivalents will enable it to fund its current operating plan commitments for more than two years.